Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8507 |
High Similarity |
NPD1091 |
Approved |
0.8489 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.8369 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8369 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8345 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.8258 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.825 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.8102 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.8085 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8074 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.8065 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.8028 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.8014 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.7975 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7974 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7931 |
Intermediate Similarity |
NPD5124 |
Phase 1 |
0.7931 |
Intermediate Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.7919 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7914 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7881 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7879 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7871 |
Intermediate Similarity |
NPD4380 |
Phase 2 |
0.7866 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7818 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7785 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7778 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7771 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7744 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7725 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7703 |
Intermediate Similarity |
NPD4538 |
Approved |
0.7703 |
Intermediate Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.7703 |
Intermediate Similarity |
NPD4536 |
Approved |
0.7688 |
Intermediate Similarity |
NPD7075 |
Discontinued |
0.7682 |
Intermediate Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.7682 |
Intermediate Similarity |
NPD1652 |
Phase 2 |
0.7639 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7636 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.761 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7603 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7603 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7597 |
Intermediate Similarity |
NPD7213 |
Phase 3 |
0.7597 |
Intermediate Similarity |
NPD7212 |
Phase 2 |
0.7584 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7552 |
Intermediate Similarity |
NPD8651 |
Approved |
0.7547 |
Intermediate Similarity |
NPD37 |
Approved |
0.7547 |
Intermediate Similarity |
NPD6801 |
Discontinued |
0.7533 |
Intermediate Similarity |
NPD5960 |
Phase 3 |
0.7533 |
Intermediate Similarity |
NPD5588 |
Approved |
0.7531 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7516 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7516 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7516 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7516 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7515 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7515 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7515 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7515 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.75 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD7843 |
Approved |
0.7484 |
Intermediate Similarity |
NPD7411 |
Suspended |
0.7484 |
Intermediate Similarity |
NPD7615 |
Clinical (unspecified phase) |
0.7483 |
Intermediate Similarity |
NPD4749 |
Approved |
0.7465 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7463 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7453 |
Intermediate Similarity |
NPD8443 |
Clinical (unspecified phase) |
0.7439 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7438 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7436 |
Intermediate Similarity |
NPD7447 |
Phase 1 |
0.7436 |
Intermediate Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.7434 |
Intermediate Similarity |
NPD1552 |
Clinical (unspecified phase) |
0.7434 |
Intermediate Similarity |
NPD1550 |
Clinical (unspecified phase) |
0.7388 |
Intermediate Similarity |
NPD290 |
Approved |
0.7386 |
Intermediate Similarity |
NPD1549 |
Phase 2 |
0.7365 |
Intermediate Similarity |
NPD6798 |
Discontinued |
0.7353 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7342 |
Intermediate Similarity |
NPD5403 |
Approved |
0.7338 |
Intermediate Similarity |
NPD7157 |
Approved |
0.7325 |
Intermediate Similarity |
NPD7410 |
Clinical (unspecified phase) |
0.7324 |
Intermediate Similarity |
NPD5126 |
Approved |
0.7324 |
Intermediate Similarity |
NPD5125 |
Phase 3 |
0.7294 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.7278 |
Intermediate Similarity |
NPD5844 |
Phase 1 |
0.7273 |
Intermediate Similarity |
NPD2424 |
Discontinued |
0.7267 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7267 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7246 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7237 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7229 |
Intermediate Similarity |
NPD6959 |
Discontinued |
0.7215 |
Intermediate Similarity |
NPD5401 |
Approved |
0.7203 |
Intermediate Similarity |
NPD6516 |
Phase 2 |
0.7203 |
Intermediate Similarity |
NPD5846 |
Approved |
0.72 |
Intermediate Similarity |
NPD6233 |
Phase 2 |
0.7195 |
Intermediate Similarity |
NPD7768 |
Phase 2 |
0.719 |
Intermediate Similarity |
NPD7033 |
Discontinued |
0.7186 |
Intermediate Similarity |
NPD3787 |
Discontinued |
0.7179 |
Intermediate Similarity |
NPD4535 |
Phase 3 |
0.7179 |
Intermediate Similarity |
NPD3750 |
Approved |
0.7178 |
Intermediate Similarity |
NPD7819 |
Suspended |
0.7162 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.7152 |
Intermediate Similarity |
NPD6799 |
Approved |
0.7134 |
Intermediate Similarity |
NPD5402 |
Approved |
0.7123 |
Intermediate Similarity |
NPD3685 |
Discontinued |
0.7115 |
Intermediate Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.7105 |
Intermediate Similarity |
NPD6355 |
Discontinued |
0.7101 |
Intermediate Similarity |
NPD7852 |
Clinical (unspecified phase) |
0.7095 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7092 |
Intermediate Similarity |
NPD6671 |
Approved |
0.7079 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD4108 |
Discontinued |
0.7073 |
Intermediate Similarity |
NPD2801 |
Approved |
0.707 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.7066 |
Intermediate Similarity |
NPD5494 |
Approved |
0.7059 |
Intermediate Similarity |
NPD968 |
Approved |
0.7048 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7043 |
Intermediate Similarity |
NPD7584 |
Approved |
0.7032 |
Intermediate Similarity |
NPD2796 |
Approved |
0.703 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7018 |
Intermediate Similarity |
NPD3751 |
Discontinued |
0.7015 |
Intermediate Similarity |
NPD940 |
Approved |
0.7015 |
Intermediate Similarity |
NPD846 |
Approved |
0.7007 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.7007 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.7007 |
Intermediate Similarity |
NPD6583 |
Phase 3 |
0.7007 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7007 |
Intermediate Similarity |
NPD6582 |
Phase 2 |
0.7005 |
Intermediate Similarity |
NPD7585 |
Approved |
0.7 |
Intermediate Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.7 |
Intermediate Similarity |
NPD5535 |
Approved |
0.6994 |
Remote Similarity |
NPD6599 |
Discontinued |
0.6993 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6987 |
Remote Similarity |
NPD5762 |
Approved |
0.6987 |
Remote Similarity |
NPD5763 |
Approved |
0.6986 |
Remote Similarity |
NPD3705 |
Approved |
0.697 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6968 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6962 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6962 |
Remote Similarity |
NPD7466 |
Approved |
0.6962 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6959 |
Remote Similarity |
NPD3225 |
Approved |
0.6952 |
Remote Similarity |
NPD7583 |
Approved |
0.6951 |
Remote Similarity |
NPD6072 |
Discontinued |
0.694 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6939 |
Remote Similarity |
NPD2981 |
Phase 2 |
0.6937 |
Remote Similarity |
NPD1511 |
Approved |
0.6933 |
Remote Similarity |
NPD8158 |
Clinical (unspecified phase) |
0.6928 |
Remote Similarity |
NPD1240 |
Approved |
0.6923 |
Remote Similarity |
NPD6100 |
Approved |
0.6923 |
Remote Similarity |
NPD6099 |
Approved |
0.6913 |
Remote Similarity |
NPD2797 |
Approved |
0.691 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.691 |
Remote Similarity |
NPD6841 |
Approved |
0.691 |
Remote Similarity |
NPD6842 |
Approved |
0.6909 |
Remote Similarity |
NPD4433 |
Discontinued |
0.6899 |
Remote Similarity |
NPD5061 |
Approved |
0.6899 |
Remote Similarity |
NPD5062 |
Approved |
0.6897 |
Remote Similarity |
NPD1357 |
Approved |
0.6893 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6886 |
Remote Similarity |
NPD3882 |
Suspended |
0.6883 |
Remote Similarity |
NPD5735 |
Approved |
0.6882 |
Remote Similarity |
NPD7680 |
Approved |
0.6882 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6879 |
Remote Similarity |
NPD6004 |
Phase 3 |
0.6879 |
Remote Similarity |
NPD6006 |
Clinical (unspecified phase) |
0.6879 |
Remote Similarity |
NPD6002 |
Phase 3 |
0.6879 |
Remote Similarity |
NPD6005 |
Phase 3 |
0.6879 |
Remote Similarity |
NPD6003 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD6667 |
Approved |
0.6875 |
Remote Similarity |
NPD6666 |
Approved |
0.6867 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.6867 |
Remote Similarity |
NPD3690 |
Phase 2 |
0.6867 |
Remote Similarity |
NPD3691 |
Phase 2 |
0.6863 |
Remote Similarity |
NPD4062 |
Phase 3 |
0.6859 |
Remote Similarity |
NPD3748 |
Approved |
0.6855 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6852 |
Remote Similarity |
NPD1512 |
Approved |
0.6842 |
Remote Similarity |
NPD7095 |
Approved |
0.6839 |
Remote Similarity |
NPD1607 |
Approved |
0.6832 |
Remote Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.6829 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6818 |
Remote Similarity |
NPD5837 |
Clinical (unspecified phase) |
0.6815 |
Remote Similarity |
NPD4477 |
Approved |
0.6815 |
Remote Similarity |
NPD1551 |
Phase 2 |
0.6815 |
Remote Similarity |
NPD4476 |
Approved |
0.6815 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6813 |
Remote Similarity |
NPD2677 |
Approved |
0.6811 |
Remote Similarity |
NPD6782 |
Approved |
0.6811 |
Remote Similarity |
NPD6779 |
Approved |
0.6811 |
Remote Similarity |
NPD6781 |
Approved |
0.6811 |
Remote Similarity |
NPD6777 |
Approved |
0.6811 |
Remote Similarity |
NPD6776 |
Approved |
0.6811 |
Remote Similarity |
NPD6778 |
Approved |
0.6811 |
Remote Similarity |
NPD6780 |
Approved |
0.681 |
Remote Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.6806 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6806 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6803 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6797 |
Remote Similarity |
NPD3268 |
Approved |
0.6795 |
Remote Similarity |
NPD2200 |
Suspended |
0.679
|
Remote Similarity |
NPD3536 |
Discontinued |